# Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

> **NCT07698535** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 64 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Cell-free Circulating Tumor DNA Assay
- **PROCEDURE:** Computed Tomography
- **DRUG:** Docetaxel
- **PROCEDURE:** PSMA PET Scan
- **PROCEDURE:** Single Photon Tomography and Computed Tomography Scan
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT07698535
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-07-05
- **Final completion:** 2029-07-05
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698535, "Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*